Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AFTER trial of adjuvant chemotherapy versus chemoradiation after radical hysterectomy for high-risk cervical cancer
jRCTs041190042Phase 3Recruiting
- Sponsor
- Japanese Gynecologic Oncology Group
- Start
- Feb 2020
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of cisplatin, paclitaxel and carboplatin in Cervical Cancer (CC) (2 arms), sponsored by Japanese Gynecologic Oncology Group. Primary endpoint: Overall survival. Started Feb 2020; status: recruiting.
02
Drugs
cisplatinpaclitaxelcarboplatin
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on jRCTs041190042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs041190042.